EN
抗体药类似物
Research Grade Cadonilimab
All
  • CatalogTD-HS870216
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsBispecific,AK-104,AK104,CAS:2394841-59-7
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Cadonilimab


Catalog No. TD-HS870216
Species reactivity Human
Applications Research Grade Biosimilar
Host species Humanized
Isotype IgG1-kappa-[scFv-heavy-lambda]2
Expression system Mammalian Cells
Clonality Monoclonal
Target Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession Q15116 & P16410
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names Bispecific,AK-104,AK104,CAS:2394841-59-7
Background Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).
Note For research use only. Not for use in clinical or therapeutic applications.

 

TD-HS870216_1.jpg
Bioactivity
 
Detects Human CD152/CTLA4 in indirect ELISAs.